Child Kidney Dis.  2022 Dec;26(2):80-85. 10.3339/ckd.22.036.

Diverse renal manifestations of Alagille syndrome in Korean children

• Joung J
• Kim MJ
• Cho H

• KMID: 2538738
• DOI: http://doi.org/10.3339/ckd.22.036

Abstract

Purpose
To determine the prevalence, clinical manifestations, and outcomes of renal involvements in pediatric Alagille syndrome (ALGS).
Methods
A total of 21 patients diagnosed with ALGS at age under 18 years who visited Samsung Medical Center from March 1999 to March 2022 were enrolled. ALGS was diagnosed either by clinical manifestations, targeted JAG1 sequencing, and/or liver biopsy. Medical records including sex, age, renal manifestations, urinalysis, serum creatinine, JAG1 sequencing, and ultrasonography were retrospectively reviewed.
Results
The male to female ratio was 9:12. The mean age of patients at confirmative diagnosis of ALGS was 18.4 months. Sanger sequencing was performed for 17 patients. Sixteen of 21 patients (76.1%) showed JAG1 mutations. Renal involvement was found in 10 patients (47.6%). The most common type of anomaly was renal dysplasia (40%). One patient having renal dysplasia was pathologically confirmed with glomerular lipid deposition. Two patients (20%) manifested nephrocalcinosis/nephrolithiasis. Among eight renal-involved patients who survived, four (50%) progressed to chronic kidney disease stage 3. Two of these chronic kidney disease patients were diagnosed with hepatorenal syndrome. The other four patients had renal functions preserved, including two without any interventions and two who underwent urological interventions.
Conclusions
The current study revealed a high prevalence of renal involvement in Korean pediatric ALGS with diverse phenotypes.

Keyword

Alagille syndrome; Chronic kidney disease; Child; Nephrocalcinosis; Renal dysplasia

Reference

References

1. Alagille D, Odievre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr. 1975; 86:63–71.

2. Kohut TJ, Gilbert MA, Loomes KM. Alagille syndrome: a focused review on clinical features, genetics, and treatment. Semin Liver Dis. 2021; 41:525–37.

3. Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol. 2013; 9:409–18.

4. Kamath BM, Podkameni G, Hutchinson AL, Leonard LD, Gerfen J, Krantz ID, et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A. 2012; 158A:85–9.

5. Danks DM, Campbell PE, Jack I, Rogers J, Smith AL. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child. 1977; 52:360–7.

6. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet. 1997; 16:243–51.

7. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006; 79:169–73.

8. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet. 1997; 16:235–42.

9. Gilbert MA, Bauer RC, Rajagopalan R, Grochowski CM, Chao G, McEldrew D, et al. Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat. 2019; 40:2197–220.

10. Bissonnette ML, Lane JC, Chang A. Extreme renal pathology in Alagille syndrome. Kidney Int Rep. 2016; 2:493–7.

11. Crosnier C, Attie-Bitach T, Encha-Razavi F, Audollent S, Soudy F, Hadchouel M, et al. JAGGED1 gene expression during human embryogenesis elucidates the wide phenotypic spectrum of Alagille syndrome. Hepatology. 2000; 32:574–81.

12. McCright B. Notch signaling in kidney development. Curr Opin Nephrol Hypertens. 2003; 12:5–10.

13. Cheng HT, Kim M, Valerius MT, Surendran K, Schuster-Gossler K, Gossler A, et al. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development. 2007; 134:801–11.

14. Surendran K, Boyle S, Barak H, Kim M, Stomberski C, McCright B, et al. The contribution of Notch1 to nephron segmentation in the developing kidney is revealed in a sensitized Notch2 background and can be augmented by reducing Mint dosage. Dev Biol. 2010; 337:386–95.

15. Goodyer P, Gupta IR. Renal dysplasia/hypoplasia. In : Avner E, Harmon WE, Niaudet P, Yoshikawa N, Emma F, Goldstein SL, editors. Pediatric nephrology. 7th ed. Berlin: Springer;2016. p. 115–34.

16. Mattoo TK, Mathews R, Gupta IR. Vesicoureteral reflux and renal scarring in children. In : Avner E, Harmon WE, Niaudet P, Yoshikawa N, Emma F, Goldstein SL, editors. Pediatric nephrology. 7th ed. Berlin: Springer;2017. p. 1715–48.

17. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976; 58:259–63.

18. CKD Work Group. KDIGO 2012 clinical practice guideline for the evalua­tion and management of chronic kidney disease. Kidney Int Suppl [Internet]. 2013. [cited 2022 Oct 31];3:1-150. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.

19. Liu PM, de Carvalho ST, Fradico PF, Cazumba ML, Campos RG, Simoes E Silva AC. Hepatorenal syndrome in children: a review. Pediatr Nephrol. 2021; 36:2203–15.

20. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019; 71:811–22.

21. Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr. 1987; 110:195–200.

22. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr. 1995; 127:220–4.

23. Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr. 1999; 29:431–7.

24. Di Pinto D, Adragna M. Renal manifestations in children with Alagille syndrome. Arch Argent Pediatr. 2018; 116:149–53.

25. Habib R, Dommergues JP, Gubler MC, Hadchouel M, Gautier M, Odievre M, et al. Glomerular mesangiolipidosis in Alagille syndrome (arteriohepatic dysplasia). Pediatr Nephrol. 1987; 1:455–64.

26. Russo PA, Ellis D, Hashida Y. Renal histopathology in Alagille’s syndrome. Pediatr Pathol. 1987; 7:557–68.

27. Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2009; 4:838–44.

28. Garcia-Nieto V, Negrete-Pedraza F, Lopez-Garcia M, Luis-Yanes MI. Are simple renal cysts in childhood associated with kidney stones? Nephrourol Mon. 2012; 4:596–8.

29. Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993; 22:513–9.